KLINITOX®
Botulinum Toxin Type A
Technical and promotional product information for qualified healthcare professionals evaluating botulinum toxin type A for medical-aesthetic use.
Pharmaceutical clarity with premium medical presentation.
KLINITOX® is presented as a botulinum toxin type A product concept focused on precision, controlled handling, professional documentation and confidence for medical-aesthetic channels.
Technical presentation designed to communicate precision.
The lyophilized powder image highlights the visual identity of the vacuum drying method and reinforces the technical and pharmaceutical positioning of KLINITOX®.
Mechanism of action and professional profile.
Botulinum toxin type A acts by selectively inhibiting presynaptic acetylcholine release at the neuromuscular junction.
Composition and dilution reference.
| Diluent Added | Resulting Dose |
|---|---|
| 1.0 mL | 10.0 Units / 0.1 mL |
| 2.0 mL | 5.0 Units / 0.1 mL |
| 4.0 mL | 2.5 Units / 0.1 mL |
Professional safety considerations.
Potential adverse effects
- Muscle weakness
- Dysphagia
- Ptosis
- Diplopia
Contraindications
- Hypersensitivity to botulinum toxin
- Neuromuscular junction disorders
- Pregnancy and lactation
Request professional information.
Professional inquiries, documentation requests and international commercial information.